Announced details
AI drug discovery, disease-structure analysis, drug discovery target identification, and disease areas with significant unmet medical needs, including cancer
Shortened the target discovery process from approximately 2 years to 2 days. From approximately 20,000 human genes, 17 genes were identified, and growth inhibition in pancreatic cancer cells was confirmed for 6 genes.
Drug Discovery AI Factory has been adopted by multiple major pharmaceutical companies (company names and number of companies undisclosed)
Since 2022, the parties have conducted joint research on disease-structure analysis and drug discovery target identification. With the launch of the joint research center, FRONTEO will be responsible for generating hypotheses using AI, while Institute of Science Tokyo will conduct experimental validation.
Location: Meguro-ku, Tokyo; President: Otake Naoto (大竹尚登). A research institution designated as a University for International Excellence.
University for International Excellence designation
Ministry of Education, Culture, Sports, Science and Technology
Within Institute of Science Tokyo’s Yokohama Campus
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Institute of Science Tokyo news; FRONTEO press releases dated 29 September 2022 and 13 May 2025; Ministry of Education, Culture, Sports, Science and Technology, “Designation of Universities for International Excellence”
| Item | Details |
|---|---|
| Names of Products / Services Covered | FRONTEO AI Drug Discovery Ecosystem Collaborative Research Center, Drug Discovery AI Factory, KIBIT, PLOM-CON analysis method, Reseal cell technology |
| Counterparty | Institute of Science Tokyo |
| Counterparty overview | Location: Meguro-ku, Tokyo; President: Otake Naoto (大竹尚登). A research institution designated as a University for International Excellence. |
| Relationship with the Company | Since 2022, the parties have conducted joint research on disease-structure analysis and drug discovery target identification. With the launch of the joint research center, FRONTEO will be responsible for generating hypotheses using AI, while Institute of Science Tokyo will conduct experimental validation. |
| Contract Date | 27 April 2026 (signing ceremony held; formal contract or agreement execution date not specified) |
| Launch date | 1 April 2026 (already open) |
| Applicable area | AI drug discovery, disease-structure analysis, drug discovery target identification, and disease areas with significant unmet medical needs, including cancer |
| Award/certification name | University for International Excellence designation |
| Awarding / certifying body | Ministry of Education, Culture, Sports, Science and Technology |
| Location | Within Institute of Science Tokyo’s Yokohama Campus |
| Quantitative Effects | Shortened the target discovery process from approximately 2 years to 2 days. From approximately 20,000 human genes, 17 genes were identified, and growth inhibition in pancreatic cancer cells was confirmed for 6 genes. |
| Usage history | Drug Discovery AI Factory has been adopted by multiple major pharmaceutical companies (company names and number of companies undisclosed) |
| Source | Institute of Science Tokyo news; FRONTEO press releases dated 29 September 2022 and 13 May 2025; Ministry of Education, Culture, Sports, Science and Technology, “Designation of Universities for International Excellence” |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To fully develop collaboration from basic research through practical application, building on the results of their joint research to date on disease-structure analysis and drug discovery target identification.